Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma

Lymphoma

This study will have two Phases: Phase 1a and Phase 1b. The goal of Phase 1a of this clinical
study is to learn more about the safety, tolerability and dosing of study drug KITE-197, in
participants with relapsed or refractory large B-cell lymphoma (r/rLBCL). The goal of Phase
1b of this clinical study is learn about the effectiveness of the recommended dose of
KITE-197 in participants with r/r LBCL.

The primary objectives of this study are:

Phase 1a: To evaluate the safety of KITE-197 in participants with r/r LBCL and determine the
target dose level for Phase 1b.

Phase 1b: To evaluate the efficacy of KITE-197 in participants with r/r LBCL as measured by
the complete remission (CR) rate.
Lymphoma
I
Jallouk, Andrew
NCT06079164
VICC-DTCTT23136P

Pembrolizumab after Radiation Therapy and Chemotherapy in Treating Patients with Limited Stage Small Cell Lung Cancer

Lung

This phase II trial studies how well pembrolizumab after standard treatment with radiation plus the following chemotherapy drugs: cisplatin or carboplatin, plus etoposide works in treating patients with limited stage small cell lung cancer (LS-SCLC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab after standard treatment with radiation plus chemotherapy may increase the ability of the immune system to fight LS-SCLC.
Lung
II
Whitaker, Ryan
NCT06140407
VICCTHO22114

Evaluation of Patient Reported Outcomes in Patients with Digestive System and Lung Neuroendocrine Cancer, NET-PRO study

Gastrointestinal

This study evaluates the patient reported outcomes in patients with digestive system neuroendocrine cancer and lung neuroendocrine cancer. Patients with neuroendocrine cancer usually have a high symptom burden which may have a negative effect on health-related quality of life (HRQoL). Patient questionnaires gather information describing symptoms and effect on quality of life, cancer type and any treatments received. Studying quality of life in patients receiving treatment for neuroendocrine cancers may help identify the effects of treatment and improve future treatment plans. Information gathered from this study may help researchers understand whether patient's diagnosis, symptoms, and order of cancer treatments have any effect on quality of life.
Gastrointestinal
N/A
Ramirez, Robert
NCT05064150
VICCGI2247

Cancer Patient Safety Learning Laboratory (CaPSLL): Preventing Clinical Deterioration in Outpatients

Multiple Cancer Types

Head/Neck, Lung
N/A
Weinger, Matthew
VICCMD1998

A Quality Improvement Initiative to Prevent Venous Thromboembolism (VTE) Among Gynecologic Oncology Patients Undergoing Chemotherapy

Multiple Cancer Types

Cervical, Gynecologic, Ovarian
N/A
Brown, Alaina
VICCGYN19119

Validating an Integrated Biomarker and Imaging Approach in the Evaluation of Indeterminate Pulmonary Nodules.

Lung

Lung
N/A
Grogan, Eric
VICCTHO2002

von Willebrand Factor in Pregnancy (VIP) Study: A Multicenter Study of Wilate Use in von Willebrand Disease for Childbirth

Hematologic

Hematologic
N/A
Wheeler, Allison
VICCNCBH2005

Pain Sensitivity and Unpleasantness in People with Alzheimer's Disease and Cancer.

Multiple Cancer Types

Breast, Prostate
N/A
Bruehl, Stephen
VICCMD2026

Biomarker Analysis of Breast Cancer Patients Receiving Immunotherapy

Breast

Breast
N/A
Balko, Justin
VICCBRE2065

Patient and Health Care Provider Perspectives of Naloxone

Miscellaneous

Miscellaneous
N/A
Hande, Karen
VICCSUPP2068

Clinical Trials Search CTA Inline Referral Form

To learn more about any of our clinical
trials, call 615-936-8422.